Skip to main content
. Author manuscript; available in PMC: 2019 Sep 20.
Published in final edited form as: Cell. 2018 Sep 13;175(1):133–145.e15. doi: 10.1016/j.cell.2018.08.020

Figure 7: Casp2 inhibition prevents NASH.

Figure 7:

A) Experimental scheme. After 6 weeks on HFD, MUP-uPA mice were treated with Ac-VDVAD (10 μg/g) for 6 weeks while kept on HFD. B) FFPE sections of inhibitor or vehicle treated livers were evaluated for macrovesicular fat, ballooning hepatocytes, MDB and p62 aggregates, macrophages, collagen fibers, and lipid droplets. Magnification bar: 100 μm. Images were quantitated as above; results are shown on right as mean ± SEM (Vehicle: n = 6; Ac-VDVAD: n = 7). C) qRT-PCR of inflammatory and fibrogenic mRNAs (Vehicle: n = 6; Ac-VDVAD: n = 7). Mean ± SEM. D) TG and cholesterol in serum and liver of treated mice (Vehicle: n = 6; Ac-VDVAD: n = 7). E) Adipocytes were visualized by H&E staining of FFPE epidydimal fat sections from inhibitor- or vehicle-injected mice. Adipocyte size and density were determined as above. ATM were stained for F4/80 and quantified. F) SREBP1/2 were IB’d in WCL and NE from livers of untreated and treated mice. G) AMPK IB of liver and muscle extracts.